Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...

AbbVie has delivered strong YTD outperformance, with shares up nearly 30% and robust analyst optimism, but I maintain a 'Hold ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price ...

Skyrizi (risankizumab-rzaa) and Humira (adalimumab) are prescription drugs that treat conditions such as psoriatic arthritis. The cost of both drugs depends on several factors. Skyrizi and Humira are ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

AbbVie’s immunology heirs Skyrizi and Rinvoq are proving booming growth to make up for once-king Humira’s continuous sales slide. With an upcoming FDA decision for Skyrizi and a new edge over a major ...

These robust surges underscore AbbVie’s ability for swift gains, indicating that upcoming catalysts could propel the stock to notable new heights once again.

People with Crohn’s disease often take medicines to help manage their condition and improve their symptoms. Some of these medicines are taken by mouth and stay inside of the digestive tract. But ...

Skyrizi is a prescription drug used to treat certain autoimmune conditions, such as Crohn’s disease, in adults. There are currently no known interactions between Skyrizi and other medications, alcohol ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...